NCAM1 and metastatic melanoma: There was no significant difference in PD-1 expression between primary and metastatic melanoma Figure 3B. CD4 and the DC surface marker CD1a were significantly decreased in metastatic melanoma, while CD19 (B cell marker) and CD56 (NK cell marker) were increased in metastatic melanoma.